Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Expanding P/E Saved This Pharma Investment

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

So much for Bristol-Myers Squibb's (NYSE: BMY  ) long-term post-Plavix guidance.

Three years ago, the company told investors not to worry. It had a plan to replace the $6 billion drug that lost patent protection last year. This year's adjusted earnings were supposed to be at least $1.95 per share, higher than the company had in 2009.

Today, the pharma company said it expects adjusted earnings for this year to come in between $1.70 to $1.78 per share, down from the $1.78 to $1.88 per share estimate that Bristol-Myers gave at the beginning of the year, and well below the $1.85 per share Bristol-Myers posted in 2009.

Blame it on the new kids
There was no doubt that Plavix sales were going to plummet; second-quarter sales were down 94% year over year. Bristol-Myers needed the new drugs to step up and fill the gap, but that didn't happen.

Diabetes drug Bydureon, which Bristol-Myers and AstraZeneca (NYSE: AZN  ) picked up in the acquisition of Amylin, produced sales of just $66 million in the second quarter. The drug, which only has to be injected weekly, was supposed to have much higher demand than the twice-daily formulation Byetta, which brought in $104 million in the second quarter. Eli Lilly (NYSE: LLY  ) selling back the drugs to Amylin might have been the pharma's best move of 2011 -- perhaps this decade -- the company hasn't had that many wins recently.

Investors also have high hopes for Eliquis, which Bristol-Myers sells with Pfizer, but the drug managed just $12 million in the second quarter, down from $17 million in its first quarter of the launch. The lower sales are likely due to stocking in the first quarter, but even so, it's clear Bristol-Myers and Pfizer are having a challenging time penetrating the heart-drug market. Eliquis has to compete with Bayer and Johnson & Johnson's Xarelto and Boehringer Ingelheim's Pradaxa, which had a year or more head start. Sales of Xarelto in the second quarter came in at $189 million in the second quarter, nearly four times as much as Johnson & Johnson and Bayer sold in the year-ago quarter, so there's clearly a market for the drugs. Pfizer and Bristol-Myers just need to put a little more muscle into the marketing.

Changing expectations
Despite having gone nowhere with earnings -- backwards actually -- shares have increased more than 70% since the original long-term guidance was issued, trumping the S&P 500.

BMY Chart

BMY data by YCharts

Investors are willing to pay more for less because they have expectations that next year -- and the year after -- will be better. Whether you look at forward P/E based on analysts' estimates, or earnings from the trailing 12 months, Bristol-Myers' P/E ratio has increased substantially.

BMY PE Ratio TTM Chart

BMY P/E Ratio data by YCharts

I think an expanding P/E was reasonable -- expectations were awfully low a few years ago -- but investors have to be careful at this point. There's little room for further expansion of the P/E. If Bristol-Myers shares are going to go higher, the company is going to have to do it the old fashion way: improving earnings.

While investors wait for increasing earnings, they'll get a nice dividend paycheck once a quarter. If you're looking for other companies that offer strong dividends, check out these nine companies that the Motley Fools' analyst have deemed "rock solid." You can get a free copy of the report by clicking here.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2559789, ~/Articles/ArticleHandler.aspx, 9/25/2016 4:58:39 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:00 PM
BMY $56.48 Up +0.06 +0.11%
Bristol-Myers Squi… CAPS Rating: ****
AZN $33.97 Down -0.31 -0.90%
AstraZeneca CAPS Rating: ****
LLY $81.16 Down -0.13 -0.16%
Eli Lilly and Co. CAPS Rating: ***